Zai Lab finds lat­est tar­get in Re­gen­eron’s bis­pe­cif­ic, pay­ing up to $190M for Chi­nese rights

Nine months af­ter hint­ing they might have bis­pe­cif­ic an­ti­bod­ies in the works, Shang­hai-based Zai Lab has signed on to help com­mer­cial­ize one of biotech’s most promis­ing can­di­dates.

Zai Lab and Re­gen­eron have signed a deal to de­vel­op and com­mer­cial­ize REGN1979, their CD20XCD3 bis­pe­cif­ic now be­ing test­ed in a range of blood can­cers, in main­land Chi­na, Hong Kong, Tai­wan and Macau. Zai Lab will pay Re­gen­eron $30 mil­lion and up to $160 mil­lion in de­vel­op­men­tal and sales mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER